This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Ardies, C. M. Search for Related Content PubMed PubMed Citation Articles by Ardies, C. M. Social Bookmarking                         What's this?

Inflammation as Cause for Scar Cancers of the Lung

Northeastern Illinois University, Chicago, Illinois, mardies1{at}aol.com

The molecular and cellular basis of inflammation has become a topic of great interest of late because of the association between mechanisms of inflammation and risk for cancer. Inflammatory-mediated events, such as the production of reactive oxygen species (ROS), the activation of growth factors (for wound repair), and the altering of signal-transduction processes to activate cell-proliferation (to replace necrotic/apoptotic tissue cells), events that also can occur independently of inflammation, are all considered to be components of risk for a variety of cancers. Using scar cancer of the lung as an example, mechanisms of inflammation associated with recurring infections with Mycobacterium tuberculosis are discussed in the context that they may, in fact, be the major or sole cause of a cancer. Production of ROS, prostaglandins, leukotrienes, and cytokines in pulmonary tissues is greatly enhanced due to a cell-mediated immune response against macrophages infected with M. tuberculosis . These responses lead to the extensive fibrosis associated with recurring infections, possibly leading to decreased clearance of lymph and lymph-associated particles from the infected region. They also will enhance rates of cell division by inhibiting synthesis of P21, leading to enhanced progression from G0 arrest to G1 phase, from G1 to Sphase, and from G2 to M phase of the cell cycle. By increasing rates of oxidative DNA damage and inhibiting apoptosis by enhancing synthesis of BCL-2, mutagenesis of progeny cells is enhanced, and these effects coupled with enhanced angiogenesis stimulated by COX-2 products lead to an environment that is highly conducive to tumorigenesis. Based on the evidence, it appears that but for an inflammatory response to recurring infections, some cases of scar cancer would not exist. By making appropriate lifestyle and dietary changes, a variety of anti-inflammatory effects can be produced, which should attenuate inflammation-induced risk for cancer.

Key Words: inflammation • infection • cancer • risk • prevention

Integrative Cancer Therapies, Vol. 2, No. 3, 238-246 (2003)
DOI: 10.1177/1534735403256332


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				I. Fabreguet, F. Francis, M. Lemery, L. Choudat, T. Papo, and K. Sacre A 76-Year-Old Man With Multiple Pulmonary Nodules Chest, April 1, 2009; 135(4): 1094 - 1097. [Full Text] [PDF]

				Y.-Y. Yu, P. F. Pinsky, N. E. Caporaso, N. Chatterjee, M. Baumgarten, P. Langenberg, J. P. Furuno, Q. Lan, and E. A. Engels Lung Cancer Risk Following Detection of Pulmonary Scarring by Chest Radiography in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Arch Intern Med, November 24, 2008; 168(21): 2326 - 2332. [Abstract] [Full Text] [PDF]

				M GORENBERG, R BAR-SHALOM, and O ISRAEL Patterns of FDG uptake in post-thoracotomy surgical scars in patients with lung cancer Br. J. Radiol., October 1, 2008; 81(970): 821 - 825. [Abstract] [Full Text] [PDF]

				H. Zhang, L. A. Garcia Rodriguez, and S. Hernandez-Diaz Antibiotic Use and the Risk of Lung Cancer Cancer Epidemiol. Biomarkers Prev., June 1, 2008; 17(6): 1308 - 1315. [Abstract] [Full Text] [PDF]

				P. Suadicani, H. O. Hein, and F. Gyntelberg ABO phenotypes and inflammation-related predictors of lung cancer mortality: the Copenhagen Male Study - a 16-year follow-up Eur. Respir. J., July 1, 2007; 30(1): 13 - 20. [Abstract] [Full Text] [PDF]

				L. S. Angelo and R. Kurzrock Vascular Endothelial Growth Factor and Its Relationship to Inflammatory Mediators Clin. Cancer Res., May 15, 2007; 13(10): 2825 - 2830. [Abstract] [Full Text] [PDF]

				D D Sin, L Wu, J A Anderson, N R Anthonisen, A S Buist, P S Burge, P M Calverley, J E Connett, B Lindmark, R A Pauwels, et al. Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease Thorax, December 1, 2005; 60(12): 992 - 997. [Abstract] [Full Text] [PDF]

				J. T. Mao, I-H. Tsu, S. M. Dubinett, B. Adams, T. Sarafian, F. Baratelli, M. D. Roth, and K. J. Serio Modulation of Pulmonary Leukotriene B4 Production by Cyclooxygenase-2 Inhibitors and Lipopolysaccharide Clin. Cancer Res., October 15, 2004; 10(20): 6872 - 6878. [Abstract] [Full Text] [PDF]